In Vitro Activity of the New Difluorinated Quinolone Sparfloxacin (AT-4140) Against Mycobacterium Tuberculosis Compared with Activities of Ofloxacin and Ciprofloxacin

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1991 Sep 1

PMID 1952872

Citations 18

Authors

N Rastogi

K S Goh

Affiliations

Soon will be listed here.

Abstract

MICs of the new fluoroquinolone drugs ofloxacin, ciprofloxacin, and sparfloxacin (AT-4140) for 10 strains of Mycobacterium tuberculosis were determined by using both a BACTEC radiometric method and testing on solid 7H11 agar medium. Radiometric MICs by 7H12 broth testing ranged from 0.5 to 1.0, 0.25 to 0.5, and 0.1 to 0.2 microgram/ml for ofloxacin, ciprofloxacin, and sparfloxacin respectively, whereas MICs in solid medium ranged from 0.5 to 1.0, 0.5 to 1.0, and 0.2 to 0.5 microgram/ml, respectively. The bactericidal action of the quinolones compared with their reported peak concentrations in human serum showed that sparfloxacin is the most bactericidal, followed by ciprofloxacin and ofloxacin. Our results suggest the potential of the new difluorinated quinolone sparfloxacin for use against the tubercle bacillus and indicate that further determination of its antimycobacterial spectrum and intracellular efficacy may be fruitful.

Citing Articles

Antituberculosis therapy for 2012 and beyond.

Lauzardo M, Peloquin C Expert Opin Pharmacother. 2012; 13(4):511-26.

PMID: 22332895 PMC: 3839627. DOI: 10.1517/14656566.2012.657176.

Tuberculosis pharmacotherapy: strategies to optimize patient care.

Mitnick C, McGee B, Peloquin C Expert Opin Pharmacother. 2009; 10(3):381-401.

PMID: 19191677 PMC: 2674232. DOI: 10.1517/14656560802694564.

Tuberculosis chemotherapy: current drug delivery approaches.

du Toit L, Pillay V, Danckwerts M Respir Res. 2006; 7:118.

PMID: 16984627 PMC: 1592088. DOI: 10.1186/1465-9921-7-118.

Antimycobacterial activities of novel levofloxacin analogues.

Kawakami K, Namba K, Tanaka M, Matsuhashi N, Sato K, Takemura M Antimicrob Agents Chemother. 2000; 44(8):2126-9.

PMID: 10898685 PMC: 90023. DOI: 10.1128/AAC.44.8.2126-2129.2000.

Ciprofloxacin once daily versus twice daily for the treatment of pulmonary tuberculosis.

BERGSTERMANN H, Ruchardt A Infection. 1997; 25(4):227-32.

PMID: 9266262 DOI: 10.1007/BF01713149.

References

Gerding D, Hitt J . Tissue penetration of the new quinolones in humans. Rev Infect Dis. 1989; 11 Suppl 5:S1046-57. DOI: 10.1093/clinids/11.supplement_5.s1046. View

Leysen D, Haemers A, PATTYN S . Mycobacteria and the new quinolones. Antimicrob Agents Chemother. 1989; 33(1):1-5. PMC: 171410. DOI: 10.1128/AAC.33.1.1. View

Nakamura S, Kurobe N, Ohue T, Hashimoto M, Shimizu M . Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother. 1990; 34(1):89-93. PMC: 171525. DOI: 10.1128/AAC.34.1.89. View

Rastogi N, Goh K, David H . Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother. 1990; 34(5):759-64. PMC: 171687. DOI: 10.1128/AAC.34.5.759. View

Rastogi N . Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Rv multiplying in the J-774 macrophage cell line. Zentralbl Bakteriol. 1990; 273(2):195-9. DOI: 10.1016/s0934-8840(11)80249-5. View

Rastogi N, Goh K . Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine. Antimicrob Agents Chemother. 1990; 34(11):2061-4. PMC: 171999. DOI: 10.1128/AAC.34.11.2061. View

Yajko D, Sanders C, Nassos P, Hadley W . In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Antimicrob Agents Chemother. 1990; 34(12):2442-4. PMC: 172081. DOI: 10.1128/AAC.34.12.2442. View

Siddiqi S, Libonati J, MIDDLEBROOK G . Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 1981; 13(5):908-12. PMC: 273915. DOI: 10.1128/jcm.13.5.908-912.1981. View

Davies S, Sparham P, Spencer R . Comparative in-vitro activity of five fluoroquinolones against mycobacteria. J Antimicrob Chemother. 1987; 19(5):605-9. DOI: 10.1093/jac/19.5.605. View

10.

Berlin O, Young L, Bruckner D . In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother. 1987; 19(5):611-5. DOI: 10.1093/jac/19.5.611. View

11.

Koga H . High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1987; 31(12):1904-8. PMC: 175825. DOI: 10.1128/AAC.31.12.1904. View

12.

Wise R, Griggs D, Andrews J . Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Rev Infect Dis. 1988; 10 Suppl 1:S83-9. View

13.

Rastogi N, Goh K, David H . Activity of five fluoroquinolones against Mycobacterium avium-intracellulare complex and M. xenopi. Ann Inst Pasteur Microbiol. 1988; 139(2):233-7. DOI: 10.1016/0769-2609(88)90008-7. View

14.

Heifets L . Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle. 1987; 68(4):267-76. DOI: 10.1016/0041-3879(87)90067-5. View

15.

Van der Auwera P, Matsumoto T, Husson M . Intraphagocytic penetration of antibiotics. J Antimicrob Chemother. 1988; 22(2):185-92. DOI: 10.1093/jac/22.2.185. View

16.

Nakamura S, Minami A, Nakata K, Kurobe N, Kouno K, Sakaguchi Y . In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989; 33(8):1167-73. PMC: 172618. DOI: 10.1128/AAC.33.8.1167. View